Tvardi Therapeutics (NASDAQ:TVRD) Stock Price Up 0.2% - Here's What Happened

Key Points

• Tvardi Therapeutics' stock price rose by 0.2% to close at $33.83 after trading as high as $35.20, with trading volume increasing by 47% from its average.
• Wall Street analysts have set a consensus rating of "Buy" for the stock, with an average price target of $64.25, indicating potential growth for investors.
• The company reported losses of $1.00 EPS for the last quarter, significantly missing analyst expectations, and has a negative return on equity of 565.83%.

Tvardi Therapeutics, Inc. (NASDAQ:TVRD - Get Free Report)'s stock price shot up 0.2% on Tuesday . The company traded as high as $35.20 and last traded at $33.83. 32,459 shares traded hands during trading, an increase of 47% from the average session volume of 22,091 shares. The stock had previously closed at $33.76.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on TVRD. Cantor Fitzgerald initiated coverage on Tvardi Therapeutics in a research note on Friday, July 11th. They set an "overweight" rating and a $52.00 price objective on the stock. Raymond James Financial initiated coverage on shares of Tvardi Therapeutics in a research note on Monday, July 14th. They issued an "outperform" rating and a $62.00 target price on the stock. Wall Street Zen raised shares of Tvardi Therapeutics to a "hold" rating in a research note on Saturday, May 24th. Finally, Piper Sandler initiated coverage on shares of Tvardi Therapeutics in a research note on Thursday, June 12th. They issued an "overweight" rating and a $78.00 target price on the stock. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $64.25.

Tvardi Therapeutics Stock Performance

The stock has a 50-day moving average of $28.19.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.

Institutional Investors Weigh In On Tvardi Therapeutics

Hedge funds have recently modified their holdings of the business. Geode Capital Management LLC purchased a new stake in shares of Tvardi Therapeutics in the second quarter valued at about $2,617,000. Marshall Wace LLP acquired a new stake in Tvardi Therapeutics during the 2nd quarter worth approximately $583,000. Bank of America Corp DE purchased a new position in Tvardi Therapeutics in the 2nd quarter valued at approximately $399,000. New York State Common Retirement Fund purchased a new position in Tvardi Therapeutics in the 2nd quarter valued at approximately $92,000. Finally, Headlands Technologies LLC acquired a new stake in Tvardi Therapeutics in the second quarter valued at approximately $80,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.